先天性肾上腺皮质增生症 中国就医指南

Congenital Adrenal Hyperplasia (CAH) is a group of autosomal recessive genetic disorders characterized by impaired cortisol biosynthesis due to enzymatic defects in the adrenal steroidogenesis pathway—most commonly 21-hydroxylase deficiency (accounting for >90% of cases). This enzymatic blockade leads to cortisol deficiency, compensatory adrenocorticotropic hormone (ACTH) overproduction, and adrenal hyperplasia. Concurrently, precursor accumulation shunts into androgen biosynthesis, resulting in prenatal or postnatal androgen excess. In classic CAH, severe enzyme deficiency manifests in infancy with life-threatening salt-wasting crises (hyponatremia, hyperkalemia, hypovolemic shock) or virilization in genetically female infants (ambiguous genitalia), while non-classic CAH presents later with premature pubarche, hirsutism, oligomenorrhea, infertility, or acne—often misdiagnosed as PCOS. Epidemiologically, classic CAH occurs in approximately 1:15,000 live births globally, with higher prevalence in certain founder populations (e.g., Ashkenazi Jews, Yupik Alaskans); non-classic CAH is more common (~1:200–1:1,000 in some ethnic groups). Risk factors include consanguinity and family history; carrier frequency is ~1:50–1:70 in general populations. From a reproductive medicine perspective, CAH profoundly impacts fertility: women may experience anovulation, chronic anovulatory cycles, and ovarian hyperandrogenism leading to subfertility or recurrent pregnancy loss; men may develop testicular adrenal rest tumors (TARTs), oligospermia, or reduced testosterone. Psychosocial burden includes gender identity concerns in severely virilized females, anxiety around fertility, lifelong medication adherence challenges, and stigma related to hirsutism or menstrual dysfunction. Quality of life is further compromised by chronic fatigue, metabolic comorbidities (insulin resistance, obesity), and increased risk of cardiovascular disease with suboptimal glucocorticoid replacement. Early diagnosis via newborn screening (17-OHP assay), timely hormonal replacement (hydrocortisone, fludrocortisone), and multidisciplinary care—including endocrinology, reproductive endocrinology, psychology, and genetics—are essential to normalize growth, preserve fertility, prevent adrenal crises, and support psychosocial well-being across the lifespan.

# 先天性肾上腺皮质增生症（CAH）治疗方案与费用明细（生殖医学科）

一、非手术/药物治疗方案

适用人群：经典型（失盐型/单纯男性化型）及非经典型CAH患者，尤其儿童期启动治疗、青春期性发育异常、生育期女性高雄激素血症或不孕者。

• •基础激素替代（氢化可的松+氟氢可的松）：

- 长效缓释制剂（如Plenadren®）：1800–2500元/月；

• •检查检验费（年度必需）：ACTH、17-OHP、雄烯二酮、电解质、骨龄评估、肾上腺超声、垂体MRI（必要时）：2800–4200元/年。

二、手术干预方案

适用人群：女性患儿外生殖器重度模糊（Prader III–V级），需阴蒂成形术+阴道成形术；男性患者罕见需手术，仅限严重睾丸肾上腺残余瘤（TART）压迫或恶变风险者。

• •微创腹腔镜TART切除术（根治性）：

- 手术+麻醉+住院（7–10天）：38,000–52,000元（含病理、术后激素调整管理）。

三、特殊复杂情况处理

• •耐药性高雄激素血症（伴胰岛素抵抗）：加用螺内酯+二甲双胍+生活方式干预，年费用4500–7200元；
• •CAH相关不孕（卵巢囊肿、排卵障碍）：促排卵联合糖皮质激素调整，周期费用6200–9800元；
• •新生儿危重失盐危象抢救（ICU支持+静脉氢化可的松）：单次住院费用25,000–40,000元。

四、方案快速选择指南

• •婴幼儿确诊者：首选药物替代+外科整形评估 → 年均支出约3.2–5.1万元；
• •育龄女性不孕/月经紊乱：激素优化+生殖内分泌干预 → 推荐中档药物+周期监测方案（4.8–7.5万元/年）；
• •TART进展或恶变疑诊：立即启动腹腔镜根治术 → 总预算≥45,000元（含术前评估与术后长期随访）。